Key Findings

Key Findings (continued)

Companies to Watch

Defining Healthcare Trends in the Future

Executive Summary—CEO’s Perspective

Market Overview—Definitions

Market Overview—Definitions (continued)

Market Overview—Definitions (continued)

Market Overview—Definitions (continued)

Market Overview—Definitions (continued)

Market Overview—Definitions (continued)

Market Overview—Segmentation

Market Overview—Segmentation (continued)

Market Overview—Segmentation (continued)

Rheumatoid Arthritis Global Incidence

Drivers and Restraints

Competitive Factors and Assessment

Competitive Landscape—Count of Marketed and Pipeline Products

Competitive Landscape—Marketed and Pipeline Products

Marketed Product Analysis

Marketed Product Analysis (continued)

Patent Expiration Timeline

Pipeline Analysis—Products in Clinical Development

Pipeline Analysis—Products in Clinical Development (continued)

Pipeline Analysis—Products in Clinical Development (continued)

Product Launch Timeline

Phase 3 Clinical Program—Next Product Launches

Product Dashboard—Eli Lilly’s Baricitinib

Product Dashboard—Sanofi/Regeneron’s SAR153191/REGN88

Product Dashboard—Biocad’s BCD-020

The Last Word—Three Big Predictions

The Last Word—Discussion

Legal Disclaimer

Market Engineering Methodology

Table of Acronyms Used

Table of Acronyms Used (continued)

Table of Acronyms Used (continued)

Drivers Explained

Drivers Explained (continued)

Drivers Explained (continued)

Drivers Explained (continued)

Restraints Explained

Restraints Explained (continued)

Additional Sources of Information on Rheumatoid Arthritis

Additional Sources of Information on Rheumatoid Arthritis (continued)

Learn More—Next Steps

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy